Signant Health to assist Shanghai Mental Health Center in trial

13th September 2019 (Last Updated September 13th, 2019 00:00)

Shanghai Mental Health Center (SMHC) has selected Signant Health to provide electronic informed consent for a neuroscience study on schizophrenia.

Signant Health to assist Shanghai Mental Health Center in trial
Invasive meningococcal disease is predominantly caused by serogroups A, B, C, Y and W-135 worldwide.

Shanghai Mental Health Center (SMHC) has selected Signant Health to provide electronic informed consent for a neuroscience study on schizophrenia.

The investigator-led trial will enrol patients at different sites in the country and will use Signant’s TrialConsent solution.

TrialConsent will use knowledge quizzes, multimedia videos, self-paced content review and other eConsent methods to help patients and their families understand the risks, benefits and expectations before enrolling in the study.

The platform will benefit the trial as the patients will be engaged. This will result in better retention of patients throughout the duration of the study, Signant Health said.

SMHC will also receive a real-time review of patient compliance and consent data and automated document management, thereby avoiding most consent-related audit findings.

SHMC Department of Psychology vice-director Dr Shen said: “SMHC was confident Signant could support the large-scale investigator-led study involving several hundred subjects across numerous hospital sites, generating significant data. Robust data collection is critical and patient-centric digitisation of the eConsent process will deliver enormous benefit to all stakeholders in this important study.”

Signant CEO Mike Nolte said: “Signant Health’s growing work in Asia supports accelerating demand from life science companies and academic partners in this region for the pioneering services we provide, our deep therapeutic area expertise, scientific and clinical consulting, and data quality analytics that leverage technology to transform the quality and impact of their research studies.”

SMHC is affiliated to the Shanghai Jiao Tong University, research university in China which works on mental health prevention.

Last month, Signant Health launched a new partner programme to collaborate with clinical research organisations (CROs) in a bid to improve clinical trials with patient-centric technology.

CRF Bracket, which was formed as a merged entity of CRF Health and Bracket, was launched as Signant Health in June.